PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE

LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 loss-of-function carriers exhibit 15–30% lower circ...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Lipid Res
Huvudupphovsmän: Ason, Brandon, van der Hoorn, José W. A., Chan, Joyce, Lee, Edward, Pieterman, Elsbet J., Nguyen, Kathy Khanh, Di, Mei, Shetterly, Susan, Tang, Jie, Yeh, Wen-Chen, Schwarz, Margrit, Jukema, J. Wouter, Scott, Rob, Wasserman, Scott M., Princen, Hans M. G., Jackson, Simon
Materialtyp: Artigo
Språk:Inglês
Publicerad: The American Society for Biochemistry and Molecular Biology 2014
Ämnen:
Research Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4617138/
https://ncbi.nlm.nih.gov/pubmed/25258384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M053207
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk